Background: The objectives of this study were to examine the cross-sectional and prospective associations of muscle functional performance as assessed by a chair rise test and brain amyloid load among nondemented older adults with spontaneous memory complaints. Methods: This is a secondary analysis, with an observational design, using data from the MAPT randomized controlled trial. Individuals assessed for brain amyloid load (florbetapir F18 positron emission tomography) and without clinical dementia (N = 269 aged 75.2 ± 4.2 years; 60.2% women) participated in the study. Cortical and regional standard uptake value ratios (SUVRs) were obtained. The main outcome measure was the 5-repetition chair rise performance (maximum speed-higher is better), which was assessed at baseline and at 6, 12, 24, and 36 months. Adjusted multiple linear (cross-sectional) and mixed-effect (overtime) regressions were performed. Results: Any of mean cortical (regions of interest) and each regional SUVRs (anterior cingulate, anterior putamen, caudate, hippocampus, medial orbitofrontal cortex, occipital cortex, parietal cortex, pons, posterior cingulate, posterior putamen, precuneus, semioval center, and temporal cortex) were not associated to chair rise after adjustment for multiplicity. These findings were obtained for both cross-sectional and prospective associations. Conclusions: Brain amyloid was not found to be associated to chair rise performance in nondemented older adults with memory complaints. Potential mechanisms on the links, if any, of amyloid load with physical performance are probably not dependent on muscle function.
The maximum speed chair rise test is a measure of muscle strength and power as applied to a functional activity. It has become an important test for studies in older adult populations dealing with functional decline because it was found to be a marker of sarcopenia (1,2) and a predictor of incident falls (3) and mortality risk (4, 5) .
Regarding cognitive function, epidemiological studies have shown that performance-based tests of physical function, including chair rise speed (6) , were predictors of future cognitive decline and dementia onset (6) (7) (8) . In parallel to these epidemiological findings, basic research has found that β-amyloid peptides into muscle fibers were associated with inclusion body myositis pathology (9-12) -an inflammatory disease that leads to sarcopenia, muscle weakness, and motor impairment-and reduced muscle strength (9) . Moreover, an autopsy-based study (13) provided evidence that people with Alzheimer's disease had more β-amyloid deposition in both brain and muscle fibers compared with people without dementia. Taken together, the above mentioned findings suggest a possible common pathway linking muscle performance and Alzheimer's disease through the β-amyloid hypothesis.
However, to the best of our knowledge, no study has investigated the associations between performance-based muscle function and amyloid load in the human brain. Our team has recently found negative associations between habitual gait speed and amyloid charge in some brain regions (14) ; nevertheless, habitual gait speed is a marker of global health (a vital sign) rather than a specific measure of muscle function. Gait speed is a comprehensive measure determined not only by muscle performance but also by dynamic balance, coordination, and even socioeconomic and cultural factors (15) , rendering it impossible to disentangle the importance of muscle performance in the gait speed-amyloid load relationships. The objective of this study was therefore to examine the cross-sectional and prospective associations of muscle functional performance as assessed by a chair rise test and brain amyloid load among older adults with spontaneous memory complaints but not dementia. We hypothesized that brain amyloid load would be negatively associated with chair rise performance.
Methods
Secondary analysis of the Multidomain Alzheimer Preventive Trial (MAPT) (16) (registration: NCT00672685), a 3-year randomized controlled trial designed to test the effects of the interventions (ie, omega-3 supplementation, or multidomain intervention involving nutritional and exercise counseling and cognitive training, or omega-3 plus multidomain intervention) against placebo on cognitive decline in elderly persons (n = 1,680). All participants signed an informed consent, and the study protocol was approved by the French Ethical Committee located in Toulouse (CPP SOOM II).
Participants
Community-dwelling, men and women without dementia, aged 70 years or older, and who met at least one of the following criteria: spontaneous memory complaints, limitation in executing one or more instrumental activity of daily living, or slow gait speed (<0.8 m/ sec). Cerebral amyloid-β deposition was assessed in 271 participants in a volunteer basis. Two persons were excluded because they had dementia (Clinical Dementia Rating [CDR] ≥ 1) at the moment of amyloid plaques' assessment. Individuals assessed for brain amyloid load and without clinical dementia (N = 269) participated in the study.
Florbetapir F 18 Positron Emission Tomography
Positron emission tomography (PET) scans were performed using florbetapir F18. Florbetapir F18 was prepared by nucleophilic substitution of a tosylate precursor (E)-2-(2-(2-(5-(4-(tert-butoxycarbonyl(methyl)amino)styryl)pyridin-2-yloxy) ethoxy)ethoxy)ethyl 4-methylbenzene sulfonate provided by Avid Radiopharmaceuticals (Philadelphia, PA) on an Raytest R&D module, according to a method validated by French authorities. Each participant underwent a cerebral PET scan, which began 50 minutes after receiving an intravenous bolus of 3.7 MBq/kg of florbetapir F18. A complete description of PET scan procedures was provided elsewhere (16, 17) . In brief, regional standard uptake value ratios (SUVRs) were obtained from semiautomated quantitative analysis with the whole cerebellum as the reference region. The brain regions assessed were anterior cingulate, anterior putamen, caudate, hippocampus, medial orbitofrontal cortex, occipital cortex, parietal cortex, pons, posterior cingulate, posterior putamen, precuneus, semioval center, and temporal cortex. Cortical-to-cerebellar SUVR (cortical SUVR) was obtained using the mean signal of the following predefined regions: frontal, temporal, parietal, precuneus, anterior cingulate, and posterior cingulate. A quality control based on semiquantification process was also performed. The threshold of 1.17 (18) was considered to define amyloid+ (A+, ie, cortical SUVR ≥ 1.17) and amyloid− (A−, ie, cortical SUVR < 1.17).
Main Outcome Measure
Chair rise performance on the 5-repetition test was assessed at baseline and at 6, 12, 24 and 36 months. This test is one of the components of the Short Physical Performance Battery (19) , a battery elaborated to evaluate lower-limb physical function. With their arms folded across their chest, participants were asked to rise from the chair and to sit down five times as quickly as possible. Time from the initial sitting position to the final standing position (after the fifth stand) was recorded. In order to obtain a continuous variable without losing people who were unable to complete the test, we calculated an arithmetic performance score, already used by others (20) , varying from 0 to 1, with 0 representing people incapable of executing the test and those having the worst performance and 1 representing the best performance. The formula used was as follows: 1 − (time in seconds for completing the 5-chair rises / time in seconds of the worst performance) (20) .
Confounders
On the basis of data availability and the literature on both dementia and physical function, we selected the following confounders: age (baseline), gender, education, body mass index (BMI: body weight divided by squared stature), cognitive status (cognitively intact vs. mild cognitive impairment [MCI] according with CDR values of 0 vs. 0.5, respectively), leisure-time physical activity (LTPA − measured as metabolic equivalent task-minutes per week) (15) , time between PET scan and baseline evaluation, time between PET scan and closest clinical assessments, MAPT group allocation, and apolipoprotein E (ApoE) ε4 status (carriers of at least one ε4 allele vs. noncarriers).
Timing of Assessments
All clinical, behavioral, and performance-based data, including the chair rise test, were obtained from the assessment performed the closest to the PET scan evaluation. The mean (SD) interval between chair rise (and all the clinical assessments) and the PET scan was 76.3 (40.6) days. Time interval between baseline and PET assessment was 512.7 ± 249.6 days (all PET scans were performed after baseline).
Statistical Analysis
Descriptive statistics are presented as mean (SD) or median (interquartile range) and percentage, as appropriate. Spearman's rank correlation was used to examine the cross-sectional relationships of chair rise with LTPA and BMI, whereas the Wilcoxon rank sum test analyzed differences in chair rise according with MCI, ApoE ε4, and amyloid status. For cross-sectional data, we ran separate multiple linear regressions for cortical SUVR and for each of the regional SUVR adjusting for all the confounders in a two-step entry: a first model with all confounders except ApoE4 status and a second regression adding ApoE4 to the previous model. This procedure was chosen because ApoE4 genotype was lacking for 12.6% of the population (ie, n = 34). Interaction terms of SUVR with group allocation (to take into account a potential bias related to MAPT interventions), CDR status (to take into account cognitive decline severity), and ApoE4 were systematically tested in the models. For analysis on the overtime evolution of chair rise performance, we ran mixedeffect models (random intercept at the participants' level) following the same adjustment procedures as earlier and using all chair rise evaluations performed after the PET scan. A sensitivity analysis was done by using all chair rise evaluations available (for the five waves of data collection), independently of the date of the assessment (meaning that chair rise tests performed before PET scans were also included); this analysis was motivated by the combination of two aspects: the relatively short interval between baseline and PET scan assessment in our sample (roughly inferior to 18 months) and the fact that β-amyloid accumulates in cortical areas of the brain very slowly and with rates of deposition of small magnitude, in median 0.02 (interquartile range: 0.00, 0.06) SUVR points per year as measured in cognitively normal people aged in average 78 (21) . Fully adjusted models were also performed stratified by amyloid positivity (separately for A+ and A−). Due to adjustments for multiplicity using Bonferroni's principle, associations were considered significant at p less than .004 (adjustments for 14 comparisons, that is, cortical SUVR plus the 13 regional SUVRs). All analyses were performed using Stata version 14 (Stata Corp., College Station, TX).
Results
Among the 269 participants, 223 (82.9%) had all five measures of chair rise, 35 (13%) had four measures, 7 (2.6%) had three measures, 3 (1.1%) had two measures, and only 1 person (0.4%) had only one available measure. The average ± SD chair rise performance (time in seconds) for each time point were as follows: baseline (n = 263), 12.1 ± 4 seconds; 6 months (n = 259), 12.2 ± 4 seconds; 12 months (n = 254), 11.7 ± 3.3 seconds; 24 months (n = 249), 12.1 ± 4.4 seconds; and 36 months (n = 241), 12.2 ± 3.9 seconds. Table 1 displays participants' characteristics. Most participants were women, older than 75 years, with high levels of education. Almost half of participants had MCI, less than one third were ApoE4 carriers, and more than one third were categorized as A+. Chair rise performance was correlated positively with LTPA (r = .17, p = .004) and negatively with BMI (r = −.26, p < .001) and was not different between people with normal cognition and MCI (p = .20), between carriers and noncarriers of the ApoE ε4 (p = .31), and between A+ and A− (p = .32). Table 2 shows the cross-sectional associations of cortical and regional amyloid charge with chair rise performance. Any of cortical SUVR and regional SUVRs were not associated to chair rise performance after adjustment for multiplicity in both Model 1 (all confounders except ApoE4; adjusted R 2 varying from 10.3% to 11.5%) and Model 2 (Model 1 plus ApoE4; adjusted R 2 varying from 8.5% to 9.3%). The percentage of variation explained by the addition of amyloid load into the regression models, as measured by the change in the adjusted R 2 between a full model and this model without the amyloid variable, was extremely low and varied from −0.1% (in the semioval center) to 1.1% (in the anterior putamen) for Model 1 and from −0.3% (in both semioval center and anterior cingulate) to 0.5% (in the anterior putamen) for Model 2. Table 3 displays the overtime associations between cortical and regional amyloid load and the evolution in chair rise performance. Hippocampus was the sole region associated to the evolution of chair rise performance, but this association was no longer significant after adjustment for multiplicity. Stratifying analysis according to amyloid status gave nonsignificant results. Adding interaction terms of SUVR with MAPT group or ApoE4 provided similar results. Once the interaction between SUVR and CDR status was added to the model, the hippocampal SUVR chair rise association became sig- Findings from the sensitivity analysis including all chair rise data available (Supplementary Table 1 ) remained unchanged, with no significant association between amyloid load and chair rise performance; adding interaction terms to the models did not change the findings after adjustment for multiplicity.
Based on the findings showing that the interaction of cognitive decline severity (ie, CDR) with SUVR in the anterior putamen (for cross-sectional analysis) and in the hippocampus (for prospective analysis) modified the associations of SUVR in these two brain Notes: ApoE = apolipoprotein E; BMI = body mass index; CDR = Clinical Dementia Rating; IQR = interquartile range; LTPA = leisure-time physical activity; MCI = mild cognitive impairment; MET = metabolic equivalent task; SUVR = standard uptake value ratios. regions with chair rise performance, we decided to inspect differences between MCI and normal cognition people in terms of chair rise. We found that the sole two persons incapable of performing the test (performance coded, therefore, as 0), when using the chair rise assessment made the closest to PET scan, had normal cognition; once we removed them from analysis, the associations of chair rise with amyloid in both the anterior putamen (Model 1: B = 0.08, 95% CI 0.01, 0.16; p = .04; Model 2: B = 0.08, 95% CI −0.00, 0.17; p = .06) and hippocampus (Model 1: B = 0.13, 95% CI 0.03, 0.24; p = .009; Model 2: B = 0.11, 95% CI 0.01, 0.22; p = .03), as well as the interaction between CDR and regional SUVR, were no longer significant after adjustment for multiplicity, suggesting that these two persons had driven the associations. Looking more deeply on these two persons, we noted that they have had normal performance on chair rise in all three measures assessed before PET scan, suggesting that an adverse event could have occurred close to PET assessment, modifying then the associations between chair rise and amyloid load artificially; indeed, one of these participants had had Notes: BMI = body mass index; CDR = Clinical Dementia Rating; CI = confidence interval; LTPA = leisure-time physical activity; MAPT = Multidomain Alzheimer Preventive Trial; PET = positron emission tomography; SUVR = standard uptake value ratio.
a Model 1 was adjusted by age, sex, education, BMI, LTPA, CDR, time between PET scan and baseline, time between PET scan and closest clinical assessments, and MAPT group allocation. Notes: BMI = body mass index; CDR = Clinical Dementia Rating; CI = confidence interval; LTPA = leisure-time physical activity; MAPT = Multidomain Alzheimer Preventive Trial; PET = positron emission tomography; SUVR = standard uptake value ratio.
a Model 1 was adjusted by age, sex, education, BMI, LTPA, CDR, time between PET scan and baseline, time between PET scan and closest clinical assessments, and MAPT group allocation. a meniscal fissure in the right knee, whereas the other had had a vertebral compression and a diagnosis of osteoporosis a few weeks/ months before the PET scan.
Discussion
This work showed that amyloid load was not associated with chair rise performance in nondemented older adults with memory complaints. This is one of the first studies investigating the relationship between brain amyloid load and muscle functional performance in humans. Although amyloid in the anterior putamen (for crosssectional data) and hippocampal amyloid (prospective data) were associated with chair rise when taking into account a potential interaction between cognitive decline severity (CDR status) and amyloid load, these associations were driven by two people with normal cognition who were incapable of doing the chair rise test probably due to adverse events (knee and vertebral injuries) in the assessment closest to PET scan; when they were removed from analysis, the associations were no longer significant.
Because no studies have investigated the associations between brain amyloid and chair rise, it is impossible to compare our results with the literature. On the basis of the scientific knowledge showing that A+ people have more functional impairment than A− (22) , that Alzheimer's disease people have high levels of both brain and muscle amyloid deposition (13) , and that intracellular β-amyloid in muscle fibers is associated with reduced muscle strength (9) (and potentially sarcopenia), allied to the results of our previous study using data from the MAPT population that found out negative associations between gait speed and regional brain amyloid (14), we have hypothesized that higher brain amyloid accumulation would be associated with lower chair rise performance, which was not the case. It is, therefore, possible that the potential mechanism through which gait speed was negatively associated to amyloid charge, as we have consistently found previously (14) , is probably not dependent on muscle function but involves other determinant(s) of gait speed (eg, balance and coordination); this hypothesis needs further exploration. Moreover, literature on the links of brain structure and function with physical fitness supports that overall physical activity and fitness mainly improve executive function and increase brain plasticity in regions that support higher-level cognitive functions, particularly the hippocampus (23) (24) (25) , leading experts to propose that links between fitness and brain function-structure would be found widespread in the brain but more consistently in the hippocampus and prefrontal cortex (23). Although we have found a trend for the hippocampal amyloid-chair rise performance relationship over time, as well as for the interaction between CDR and hippocampal SUVR on chair rise, these associations were not significant after adjustment for multiplicity.
This study has several strengths: This is the first study performed in humans investigating the associations of brain amyloid load with a specific measure of muscle functional performance (ie, muscle function applied to a functional task, such as raising from a chair); sample size is relatively large for imagery studies linking brain amyloid to clinical data; we investigated both cross-sectional and overtime associations. However, several limitations are worth mentioning: This is a secondary analysis using data from a randomized controlled trial designed to prevent cognitive decline. This issue was probably reduced by the inclusion of an interaction term between MAPT group allocation and SUVR in all models; PET scans were performed throughout the 3-year intervention in different days than clinical assessments. This, on one hand, impeded us of having a "true" cross-sectional analysis and, on the other hand, limited the follow-up length for the overtime analysis-the inclusion of time interval between clinical and PET assessments and between baseline and PET assessments into the multivariate regression models probably reduced the importance of this bias; finally, this is an observational study using a single measure of amyloid load, which impeded us of looking at the associations between changes in amyloid deposition and changes in chair rise performance.
Overall, this study showed that any of cortical or regional brain amyloid load were not associated with chair rise performance. However, the debate is far from closed, and future studies in this field should be done in order to confirm or refute our findings. When examining the association of brain amyloid with physical performance tests, taking into account the interaction between cognitive decline severity and amyloid load might be relevant. Exploring the associations between changes in amyloid load and changes in physical performance using longitudinal data with at least two time points for both measures would shed light on this topic. Future studies on this topic should use other potentially more sensitive measures of muscle function, such as electromyogram or isokinetic measurements.
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